Signum Life Science

What's happening in vaccination globally, and what does it mean for Denmark? Tine Rikke Jørgensen, Head of Vaccines DK at Sanofi, opens Signum Morning Briefing on October 20 with a look at global trends and opportunities in vaccination. She's joined by speakers from Lif, the Danish Lung Association and Statens Serum Institut, and the morning wraps up with a panel where you can ask your own questions. N.B. The event is in Danish.

Think MFN leaves with the next US administration? Think again. International price referencing is here to stay. Watch our webinar to learn what MFN means for Nordic pharma.

If affiliates outside the EU don't know how global is handling the PICOs, the JCA report comes as a surprise. It's published after the Commission decision, which is too late to use in their own submissions. Niels Juul Brogaard from Novo Nordisk on why the sharing has to happen along the way.

People with chronic diseases have the most to gain from vaccination, but they don't always get vaccinated. Ann Leistiko, CEO of the Danish Lung Association, takes on that gap at Signum Morning Briefing on October 20. She'll be talking about how we get better at vaccinating the people who need it most. She's joined by speakers from Sanofi, Lif and Statens Serum Institut, and the morning wraps up with a panel where you can ask your own questions. N.B. The event is in Danish.

The JCA only binds EU member states. But the reports are public, and Niels Juul Brogaard from Novo Nordisk expects them to be used well beyond the EU, especially by countries without the resources to run their own assessments.

It's here. SMR2 is finally live. SMR2 brings new, more complete data from the Danish Hospital Medicine Register (SMR), at patient level and linkable to other national health registers. That's where many cancer drugs and biologics sit. And we're already putting it to work in real-world evidence. For you, that means real-world answers on: → Uptake and market share → Treatment patterns and lines of therapy → Treatment duration and switching → How you compare to competitors